1. Scrip

Novartis, Pfizer Advance Their NASH Ambitions Separately, As Partners

 
• By Joseph Haas

Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.

Liver Meeting Update, Boston 2019
Pfizer, Novartis are working to launching a Phase II NASH combo study in 2020

Neither Novartis AG nor Pfizer Inc. has entered Phase III in non-alcoholic steatohepatitis (NASH) yet, but it seems that the smaller companies ahead in development should be keeping a wary eye on the two big pharmas’ NASH programs, and not just because of their developing clinical trial partnership in the space.

Novartis unveiled new data during the American Association for the Study of Liver Diseases meeting 8-12 November in Boston that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.